Financial Performance - The company's revenue for Q3 2021 was CNY 660,587,909, a decrease of 15.79% compared to the same period last year[3]. - The net profit attributable to shareholders was a loss of CNY 145,945,060.70, down 51.95% year-on-year[3]. - Total profit decreased by 374.4% year-on-year, primarily due to impairment provisions related to the sale of viscose-related asset groups[8]. - Net profit attributable to the parent company decreased by 345.58% year-on-year, driven by increased impairment provisions from asset sales[8]. - Net loss for Q3 2021 amounted to ¥935,289,063.97, compared to a net loss of ¥213,990,094.33 in Q3 2020, indicating a significant decline in profitability[20]. - The total comprehensive income for the period was -911,062,744.47 CNY, compared to -204,465,903.76 CNY in the previous period, indicating a significant decline[21]. - Basic and diluted earnings per share were both -1.17 CNY, down from -0.26 CNY in the same period last year[21]. Cash Flow - The net cash flow from operating activities was negative CNY 275,502,278.35, representing a decline of 1,213.21% compared to the previous year[3]. - Cash received from sales of goods and services increased by 46.16% year-on-year, attributed to higher sales volume and prices of viscose products[8]. - Cash paid for purchasing goods and services increased by 99.32% year-on-year, due to a rise in cash payments for raw material procurement[8]. - Cash inflow from operating activities totaled 2,192,959,888.41 CNY, an increase from 1,609,782,565.62 CNY in the previous period[24]. - The total cash outflow from operating activities was 2,468,462,166.76 CNY, compared to 1,585,034,183.39 CNY in the previous period[24]. - Cash flow from investing activities generated a net inflow of 163,518,335.51 CNY, compared to a net outflow of -200,524,727.94 CNY in the previous period[24]. - Cash flow from financing activities resulted in a net inflow of 79,504,251.23 CNY, down from 135,102,131.89 CNY in the previous year[25]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 5,312,266,850.85, a decrease of 17.34% from the end of the previous year[3]. - Total current assets increased to ¥4,291,155,642.53 as of September 30, 2021, from ¥2,876,325,243.35 at the end of 2020, reflecting a growth of 49.2%[15]. - Total liabilities decreased to ¥5,279,253,409.20 from ¥5,458,300,814.89, a reduction of 3.3%[16]. - The company's equity totaled CNY 968,302,505.62, with a capital reserve of CNY 1,151,303,231.24 and retained earnings showing a deficit of CNY 968,394,932.52[29]. - Total assets amounted to CNY 6,426,603,320.51, with current assets at CNY 2,876,325,243.35 and non-current assets at CNY 3,550,278,077.16[28]. Expenses - Other business income increased by 68.06% year-on-year, attributed to higher sales of raw materials and by-products[7]. - Other business costs rose by 126.12% year-on-year, also due to increased sales of raw materials and by-products[7]. - Research and development expenses were reported as zero for the current period, indicating no R&D activities[7]. - The company reported a significant increase in management expenses to ¥241,353,491.34, up from ¥200,849,323.32, reflecting a rise of 20.2%[20]. - Operating profit decreased by 194.93% year-on-year, mainly due to increased asset impairment provisions[8]. Impairment and Provisions - Asset impairment losses increased by 5624.44% year-on-year, primarily due to higher provisions for inventory and fixed assets[8]. - The company experienced a 3160.72% increase in advance receipts, reflecting pre-sales of certain assets during the reporting period[7]. - Investment income decreased by 100.62% compared to the same period last year, mainly due to a reduction in financial management income[8]. Other Information - The company did not undergo an audit for the third quarter report[31]. - The report indicates a significant investment in fixed assets, totaling CNY 3,267,306,561.25, with a decrease of CNY 166,175,115.23 compared to the previous period[28]. - The report was released on October 28, 2021, and is the first to apply the new leasing standards retrospectively[30].
澳洋健康(002172) - 2021 Q3 - 季度财报